PMID: 6411893Jul 1, 1983Paper

Pharmacokinetics and bioavailability of intravenous and topical nitroglycerin in the rhesus monkey: estimate of percutaneous first-pass metabolism

Journal of Pharmaceutical Sciences
R C WesterL Kosobud

Abstract

[14C]Nitroglycerin was administered intravenously and topically to three rhesus monkeys and the pharmacokinetics were determined. The rhesus monkey is an animal model for which percutaneous absorption is similar to that in the human. After intravenous administration the decline in plasma nitroglycerin concentration was biexponential with an initial half-life of 0.8 min (2-5 min postadministration) and a terminal half-life of 18 min (5-60 min postadministration). After topical application in an ointment, plasma concentrations of unchanged nitroglycerin were first detectable at 0.25 hr postapplication. Peak plasma nitroglycerin concentrations occurred between 4-6 hr, and nitroglycerin was still detectable at 24 hr postapplication. Plasma levels fit a biexponential curve with an alpha-phase half-life of 3.0 hr, a beta-phase half-life of 4.3 hr, and a lag time of 0.5 hr. The absolute bioavailability of topical nitroglycerin was 56.6 +/- 5.8%. The differences in bioavailability estimates between unchanged nitroglycerin and total carbon-14 is considered to be the amount of nitroglycerin which is metabolized as it is absorbed through the skin (percutaneous first-pass effect). This value for topical nitroglycerin was quite small, only ...Continue Reading

Citations

Sep 30, 2004·Archives of Toxicology·David J LockleyFaith M Williams
Oct 1, 1991·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·M J GrahamM D Rawlins
Jan 1, 1985·Journal of Toxicology and Environmental Health·R C Wester, H I Maibach
Dec 1, 1994·The Journal of Pharmacy and Pharmacology·K A LambP N Shaw
Jan 1, 1990·Drug Metabolism Reviews·J Kao, M P Carver
Mar 1, 1987·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·R H GuyD A Bucks
Jul 20, 2007·The Journal of Pharmacy and Pharmacology·Jhi-Joung WangJia-You Fang
Feb 20, 2009·Biopharmaceutics & Drug Disposition·Akiko FukasawaYoshiaki Matsumoto
Jul 1, 1989·Toxicology and Applied Pharmacology·S W CollierR L Bronaugh
Dec 6, 2005·The Veterinary Journal·P C Mills, S E Cross
Oct 11, 2014·The Journal of Pharmacy and Pharmacology·Guanyu ChenJingyuan Wen
Sep 1, 1995·The British Journal of Dermatology·K Aalto-Korte, M Turpeinen
Jul 1, 1985·Biopharmaceutics & Drug Disposition·S H Curry, S M Aburawi
Jan 1, 1988·Annals of the New York Academy of Sciences·J Kao
Sep 1, 1995·Anesthesiology·P FisetS L Shafer
Aug 1, 1987·Journal of Pharmacokinetics and Biopharmaceutics·E NakashimaL Z Benet
Mar 15, 2014·Paediatrics & Child Health·Samira Samiee-ZafarghandyNadya Ben Fadel
Aug 1, 1986·Journal of Pharmacokinetics and Biopharmaceutics·K Kubota, T Ishizaki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.